KZA News: KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY AN - 9th Nov 2022, 11:00pm

[annb0t]

SYDNEY, Nov. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentation at the upcoming annual meeting of the Society for Neuro-Oncology (SNO), which will be held from 17-20 November in Tampa, FL. Kazia Therapeutics Limited Logo (PRNewsfoto/Kazia Therapeutics Limited)

The ...

>>> Read more: KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING